Intraoperative Lidocaine Infusion and Surgery-induced Release of Pro-inflammatory Cytokines After Abdominal Surgery
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
Lidocaine is an amide local anaesthetic and an antiarrhythmic agent, first synthesized in
1942, and after approval for human use was launched in 1948 in Sweden The first observations
of post operative analgesic effects of perioperative intravenous lidocaine (IVL) were
initially proposed in 1951 subsequently many more enthusiastic reports followed.
Postoperative formal clinical evaluations in the perioperative setting were conducted in the
late 1950s where IV Lidocaine was demonstrated to have a postoperative analgesic effect
without posing the risk of respiratory depression, reducing the occurrence of postoperative
nausea and vomiting (PONV), and enhance post-surgical recovery. IV Lidocaine also potentiated
the depth of anesthesia and led to a better tolerance of endotracheal intubation.Around 40%
of patients experience a delay in resumption of normal bowel function after colorectal
surgery. This delay leads to symptoms of nausea, vomiting, constipation, and abdominal
distension, which then require unpleasant supportive interventions such as intravenous fluids
and nasogastric tube insertion. There is no remedy to address this delay. ALLEGRO, "A
placebo-controlled randomized trial of intravenous Lidocainein accelerating Gastrointestinal
Recovery surgery," is the latest ongoing multicenter research study across the United
Kingdom, investigating the use of intravenous lidocaine to improve recovery after colorectal
surgery